e-Drug3D
1835
L-GLUTAMINE
INN
L-GLUTAMINE
cas 56-85-9
CLASS
BLOOD
AMINOACID INDICATED TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE (SCD)
L-GLUTAMINE MAY IMPROVE THE NAD REDOX POTENTIAL IN SICKLE RBCS THROUGH INCREASING THE AVAILABILITY OF REDUCED GLUTATHIONE
ROUTE (list)
ORAL
ATC code
A16AA03
PK parameters
Tmax 0.5 HOUR
VD 13 LITER (65 KILOGRAM)
t1/2 1 HOUR
-
PDB
2F2A (STRUCTURE OF TRNA-DEPENDENT AMIDOTRANSFERASE GATCAB COMPLEXED WITH GLN)
Ligand code = GLN (link to the list of PDB complexes)
Download experimental 3D coordinates of GLN with added hydrogens
Amino acid transporter UNIPROT Q9Z1J7
Formula:
C5H10N2O3
Calculated chemical properties:
MW 145.14
NB_atoms 10
XLogP -2.67
PSA 99.745
NB_HD 4
NB_HA 5
fsp3 0.60
Lipinski(0=no;1=yes) 1
NB_atoms 10
XLogP -2.67
PSA 99.745
NB_HD 4
NB_HA 5
fsp3 0.60
Lipinski(0=no;1=yes) 1
FDA
NDA 021667 (label) INN (L-GLUTAMINE) NUTRESTORE (EMMAUS MEDCL) APPROVAL= AP YEAR= 2004 NEWMOLECULARENTITY DISCONTINUED
NDA 208587 (label) INN (L-GLUTAMINE) ENDARI (EMMAUS MEDCL) APPROVAL= AP YEAR= 2017
NDA 215647 (pdf not found) INN (L-GLUTAMINE) L-GLUTAMINE (NOVITIUM PHARMA) APPROVAL= AP YEAR= 2024
NDA 021667 (label) INN (L-GLUTAMINE) NUTRESTORE (EMMAUS MEDCL) APPROVAL= AP YEAR= 2004 NEWMOLECULARENTITY DISCONTINUED
NDA 208587 (label) INN (L-GLUTAMINE) ENDARI (EMMAUS MEDCL) APPROVAL= AP YEAR= 2017
NDA 215647 (pdf not found) INN (L-GLUTAMINE) L-GLUTAMINE (NOVITIUM PHARMA) APPROVAL= AP YEAR= 2024